Doctor profile · Federal record
Dr. Anju Vasudevan, M. D.
Medical Oncology Physician (CMS: Hematology/Oncology) · Hematology & Oncology Physician · Ocala, FL
- NPI 1043203888
- Accepts Medicare
- 45 yrs in practice
- Female
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
3130 Sw 32Nd Ave
Ocala, FL 344744445
(352) 732-4032
fax (352) 732-4191
Credentials & registration
- NPI registered
- August 2005 — 21 yrs on file
- Profile last updated
- February 27, 2023
- Year of graduation
- 1981 — 45 yrs since
- Specialty taxonomy
- 207RX0202X — NUCC code
- State license (1)
- Florida #ME52275
- Medicaid
- FL #061804700
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1043203888. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
213,076
Distinct HCPCS
10
Medicare allowed
$3,118,259
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
Q5101 |
Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 50,040 | 33 | $0 | |
J0881 |
Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 34,480 | 48 | $3 | |
J9271 |
Injection, pembrolizumab, 1 mg | 28,600 | 24 | $54 | |
J9025 |
Injection, azacitidine, 1 mg | 22,800 | 11 | $0 | |
J1437 |
Injection, ferric derisomaltose, 10 mg | 11,800 | 105 | $21 | |
J0897 |
Injection, denosumab, 1 mg | 10,800 | 106 | $23 | |
Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 7,325 | 47 | $0 | |
Q0138 |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 7,140 | 11 | $0 | |
J1453 |
Injection, fosaprepitant, 1 mg | 6,750 | 17 | $0 | |
J1568 |
Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 3,894 | 26 | $42 |
In context: peer comparison
Among 3 peers in this city , average services per provider: 2,519. This provider delivers 85× the peer median.Open Payments
Industry payments received
All-time total
$5,563
Transactions
157
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | 31 | $1,145.96 | |
| PFIZER INC. | 16 | $343.56 | |
| AstraZeneca Pharmaceuticals LP | 11 | $265.60 | |
| Astellas Pharma US Inc | 5 | $243.81 | |
| Alexion Pharmaceuticals, Inc. | 7 | $219.83 | |
| Janssen Biotech, Inc. | 17 | $212.28 | |
| Gilead Sciences, Inc. | 10 | $207.58 | |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $201.73 | |
| Merck Sharp & Dohme LLC | 8 | $181.31 | |
| Celgene Corporation | 11 | $177.34 | |
| Daiichi Sankyo Inc. | 12 | $170.08 | |
| Incyte Corporation | 7 | $164.57 | |
| Genmab U.S., Inc. | 3 | $161.78 | |
| Eisai Inc. | 9 | $158.26 | |
| Amgen Inc. | 1 | $150.00 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
1,259
Patients
455
Total drug cost
$519,940
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Letrozole | Generic | 260 | 81 | $5,622 |
| Dexamethasone | Generic | 170 | 79 | $3,597 |
| Anastrozole | Generic | 157 | 62 | $5,557 |
| Alendronate Sodium | Generic | 106 | 25 | $643 |
| Tamoxifen Citrate | Generic | 83 | 28 | $2,734 |
| Hydroxyurea | Generic | 78 | 23 | $3,028 |
| Ondansetron Hcl | Generic | 52 | 37 | $624 |
| Anagrelide Hcl | Generic | 51 | 0 | $8,032 |
| Eliquis (Apixaban) | Brand | 51 | 16 | $34,064 |
| Acyclovir | Generic | 47 | 16 | $681 |
Hospital affiliations
Frequently asked questions
What is Dr. Anju Vasudevan's medical specialty?
Dr. Anju Vasudevan practices Medical Oncology Physician in Ocala, FL.
Where does Dr. Anju Vasudevan practice?
Dr. Anju Vasudevan practices at 3130 Sw 32Nd Ave, Ocala, FL 344744445. Office phone: 3527324032.
What is Dr. Anju Vasudevan's NPI?
Dr. Anju Vasudevan's National Provider Identifier (NPI) is 1043203888, issued by NPPES.
Does Dr. Anju Vasudevan accept Medicare assignment?
Yes. Dr. Anju Vasudevan accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Anju Vasudevan commonly perform?
Top Medicare-reported procedures in 2023: Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram (HCPCS Q5101); Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS J0881); Injection, pembrolizumab, 1 mg (HCPCS J9271). Source: CMS Medicare Physician & Other Practitioners file.